(Q40620054)

22 September 2017

HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. (English)

1 reference

22 September 2017

1 reference

Chun Tao Wai

1

1 reference

22 September 2017

Chi-Jen Chu

series ordinal

2

1 reference

22 September 2017

Munira Hussain

series ordinal

3

1 reference

22 September 2017

Anna S F Lok

series ordinal

4

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

22 September 2017

1 reference

22 September 2017

36

1 reference

22 September 2017

6

1 reference

22 September 2017

1425-1430

1 reference

A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness

22 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

Management of hepatitis B: 2000--summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Clinical significance of hepatitis B virus genotypes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Hepatitis B genotypes and the response to interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Clinical relevance of hepatitis B viral mutations

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Outcome of liver disease and response to interferon treatment are not influenced by hepatitis B virus core gene variability in children with chronic type B hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Effect of multiple mutations in the core promoter and pre-core/core region of hepatitis B virus genome on the response to interferon in e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Mutations in the X region and core promoter are rare and have little impact on response to interferon therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Hepatitis B viral genotypes and lamivudine resistance.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

https://api.crossref.org/works/10.1002%2FHEP.1840360619

1 reference

7 January 2021

Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840360619

7 January 2021

Identifiers

DOI

10.1002/HEP.1840360619

1 reference

22 September 2017

1 reference